Background

What people are saying about CURE

CURE Pharmaceutical Launches New Brand Focused on Patient Needs in Medication Delivery

OXNARD, Calif., Jan. 04, 2018 (GLOBE NEWSWIRE) — CURE Pharmaceutical(OTCQB:CURR), (“CURE”), an innovative drug delivery and development company, announced the launch of… READ MORE

CURE Pharmaceutical to Present at 2018 Biotech Showcase

OXNARD, Calif., Jan. 03, 2018 (GLOBE NEWSWIRE) — CURE Pharmaceutical(OTCQB:CURR), (“CURE”), an innovative drug delivery and development company, will be a presenting… READ MORE

Cure Pharmaceutical Enters Into Product Development Agreement with Therapix Biosciences To Develop Cannabinoid-Based Product For Sleep Disorders

CURE to Manufacture Therapix Proprietary Entourage Formulation (Dronabinol and PEA)-Based Product Using Proprietary CureFilm™ Technology OXNARD, Calif., Nov. 07, 2017 (GLOBE… READ MORE

CURE Pharmaceutical Subsidiary, Oak Therapeutics, Completes Critical Milestone in Phase 1 of NIH Grant to Develop Oral Dissolvable Strip for Tuberculosis

OXNARD, Calif., Aug. 22, 2017 (GLOBE NEWSWIRE) — CURE Pharmaceutical(OTCQB:CURR), (“CURE”), a leading disruptive drug delivery technology company, today announced that its… READ MORE

CURE Pharmaceutical Launches New Academic Partnership Program Providing the Company’s Proprietary CureFilm™ for More Humane and Effective Animal Research

OXNARD, Calif., Sept. 06, 2017 (GLOBE NEWSWIRE) — CURE Pharmaceutical (OTCQB:CURR), (“CURE”), a leading disruptive drug delivery technology company, today announced the launch… READ MORE

CURE Pharmaceutical Enters Partnership to Distribute New Erectile Dysfuntion Drug Using Company’s Proprietary CureFilm™ Into Asian Market

OXNARD, Calif., Aug. 10, 2017 (GLOBE NEWSWIRE) — CURE Pharmaceutical(OTCQB:CURR), (“CURE”), a leading disruptive drug delivery technology and pharmaceutical cannabinoid molecule development… READ MORE

CURE Pharmaceutical Appoints CannaKids CEO and Cannabis Cancer Advocate Tracy Ryan to Advisory Board

OXNARD, Calif., June 27, 2017 (GLOBE NEWSWIRE) — CURE Pharmaceutical (OTCQB:CURR), (“CURE”), a leading disruptive drug delivery technology and pharmaceutical cannabinoid molecule development… READ MORE

CURE Pharmaceutical & Therapix Biosciences Signs MOU with Israel’s Assuta Medical Centers to Develop First-in-Class Therapeutic Products in Fields of Personalized Medicine & Cannabinoids

OXNARD, Calif. and TEL AVIV, Israel, July 11, 2017 (GLOBE NEWSWIRE) — CURE Pharmaceutical (OTCQB:CURR), (“CURE”), a leading disruptive drug delivery… READ MORE

Getting Healthy, Not High: Using Cannabis to Fight Cancer

“Fighting cancer. Cure Pharmaceuticals, along with its partner, the Technion-Israel Institute of Technology, will be researching cannabinoid compounds in the treatment leukemia… READ MORE

Leading OTF Manufacturer CURE Pharmaceutical Comments on New Report Showing Exponential Growth in Thin Film Drug Manufacturing Market

OXNARD, Calif., June 07, 2017 (GLOBE NEWSWIRE) — CURE Pharmaceutical (OTCQB:CURR), (“CURE”), a leading disruptive drug delivery technology and pharmaceutical cannabinoid… READ MORE

Want to stay up to date with all CURE Pharmaceutical’s updates? Sign up with your email and we will send updates.